Pfizer's $11.6B wager; TIGIT implosion; An unusual pharma-biotech pact; Inside a16z's vision to reshape biotech; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Are you headed to the BIO confab in San Diego next month? If so, do consider joining Endpoints for our return to in-person panels since the pandemic began. But don’t worry if you won’t be there — we do have plenty of virtual panels lined up. Learn more here.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.